Studies in patients with advanced melanoma carrying a BRAFV600E mutation have shown that combining BRAF and MEK inhibitors resulted in a higher rate of complete/partial responses and median progression-free survival compared with monotherapy groups [97–99]. Here, BRAF is linked to melanoma.